Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ribavirin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 2/20 | 1.00 |
| ▸ | THPO | P40225 | 2/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 2/20 | 1.00 |
| ▸ | GLA | P06280 | 1/20 | 1.00 |
| ▸ | EIF4E | P06730 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | TOP1 | P11387 | 1/20 | 1.00 |
| ▸ | PNP | P00491 | 4/20 | 0.76 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | BLM | P54132 | 2/20 | 0.56 |
| ▸ | TP53 | P04637 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | HTR2C | P28335 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ribavirin SCHEMBL427229 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2ALDH1A1TSHRADORA1 | |
| Ribavirin SCHEMBL326516 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2ALDH1A1TSHRADORA1 | |
| Ribavirin SCHEMBL12658449 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2ALDH1A1TSHRADORA1 | |
| Ribavirin SCHEMBL4064991 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2ALDH1A1TSHRADORA1 | |
| Ribavirin SCHEMBL5476700 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2ALDH1A1TSHRADORA1 | |
| Ribavirin SCHEMBL3727 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2ALDH1A1TSHRADORA1 | |
| Ribavirin SCHEMBL6027558 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2ALDH1A1TSHRADORA1 | |
| Ribavirin SCHEMBL21311208 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2ALDH1A1TSHRADORA1 | |
| Ribavirin SCHEMBL20806078 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2ALDH1A1TSHRADORA1 | |
| Ribavirin SCHEMBL1981630 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2ALDH1A1TSHRADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238323-A1 | MODIFIED NUCLEOSIDES AND NUCLEOTIDES ANALOGS AS ANTIVIRAL AGENTS FOR CORONA AND OTHER VIRUSES | EMORY UNIVERSITY | 2024-07-18 | — | — | US | disclosed |
| WO-2020118139-A1 | A1 ADENOSINE RECEPTOR AGONISTS AND METHODS OF USE THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2020-06-11 | — | — | WO | disclosed |
| US-9828409-B2 | Bridged-cyclo-ProTides as prodrugs of therapeutic nucleosides and nucleotides | ZHONG MINGHONG (US) | 2017-11-28 | — | — | US | disclosed |
| US-20170166557-A1 | 6-SUBSTITUTED QUINAZOLINONE INHIBITORS | UNIV KANSAS (US) | 2017-06-15 | — | — | US | disclosed |
| US-20170119809-A1 | Combination Therapy Using Ribavirin As eIF4E Inhibitor | UNIVERSITE DE MONTREAL (CA) | 2017-05-04 | — | — | US | disclosed |
| EP-2755983-B1 | SUBSTITUTED CARBONYLOXYMETHYLPHOSPHORAMIDATE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS | IDENIX PHARMACEUTICALS LLC (US) | 2017-03-15 | — | — | EP | disclosed |
| US-9580393-B2 | 6-substituted quinazolinone inhibitors | UNIVERSITY OF KANSAS (US) | 2017-02-28 | — | — | US | disclosed |
| US-9545416-B2 | Combination therapy using ribavirin as eIF4E inhibitor | UNIVERSITE DE MONTREAL (CA) | 2017-01-17 | — | — | US | disclosed |
| US-20160220595-A1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | DEFENSE THREAT REDUCTION AGENCY, US DOD | 2016-08-04 | — | — | US | disclosed |
| US-9403863-B2 | Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections | IDENIX PHARMACEUTICALS LLC (US) | 2016-08-02 | — | — | US | disclosed |
| US-7615535-B2 | Modulating nitric oxide acitivity with glutathione-dependent formaldehyde dehydrogenase (GS-FDH); for treatment of asthma and impotency, angina, hypertension, and cancer; enzyme inhibitors | DUKE UNIVERSITY (US) | 2009-11-10 | — | — | US | disclosed |
| US-20090176732-A1 | PROTECTED NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA INC. (US) | 2009-07-09 | — | — | US | disclosed |
| US-20090176732-A1 | PROTECTED NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA INC. (US) | 2009-07-09 | — | — | US | disclosed |
| US-20080286230-A1 | Compounds and pharmaceutical compositions for the treatment of viral infections | IDENIX PHARMACEUTICALS, INC. | 2008-11-20 | — | — | US | disclosed |
| US-20080286230-A1 | Compounds and pharmaceutical compositions for the treatment of viral infections | IDENIX PHARMACEUTICALS, INC. | 2008-11-20 | — | — | US | disclosed |
| US-7285659-B2 | Process for the preparation of D-ribavirin | ARCHIMICA S.R.L. (IT) | 2007-10-23 | — | — | US | disclosed |
| US-20070111949-A1 | Modulating nitric oxide acitivity with glutathione-dependent formaldehyde dehydrogenase (GS-FDH); for treatment of asthma and impotency, angina, hypertension, and cancer; enzyme inhibitors | DUKE UNIVERSITY | 2007-05-17 | — | — | US | disclosed |
| US-7179791-B2 | Modulating nitric oxide acitivity with glutathione-dependent formaldehyde dehydrogenase (GS-FDH); for treatment of asthma and impotency, angina, hypertension, and cancer; enzyme inhibitors | DUKE UNIVERSITY (US) | 2007-02-20 | — | — | US | disclosed |
| US-20070037773-A1 | Methods and compositions for treating flaviviruses and pestiviruses | IDENIX PHARMACEUTICALS LLC | 2007-02-15 | — | — | US | disclosed |
| US-20070037735-A1 | 2' and 3'-nucleoside prodrugs for treating Flaviviridae infections | IDENIX PHARMACEUTICALS, INC. | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170119809-A1 | Combination Therapy Using Ribavirin As eIF4E Inhibitor | EIF4EBP1, EIF4E, GLI1 | LMNA 1706/4885SMN1; SMN2 2453/4885ALDH1A1 3572/4885 |
| US-20160220595-A1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | PNP, NTPCR, TYMP | LMNA 2417/4885SMN1; SMN2 1254/4885ALDH1A1 1897/4885 |
| US-20070037735-A1 | 2' and 3'-nucleoside prodrugs for treating Flaviviridae infections | PNP, NSUN2, HAVCR2 | LMNA 981/4885SMN1; SMN2 626/4885ALDH1A1 465/4885 |
| US-20090176732-A1 | PROTECTED NUCLEOTIDE ANALOGS | NTPCR, NT5C2, PNP | LMNA 777/4885SMN1; SMN2 581/4885ALDH1A1 941/4885 |
| US-20080286230-A1 | Compounds and pharmaceutical compositions for the treatment of viral infections | HAVCR2, PYGL, GYS2 | LMNA 1561/4885SMN1; SMN2 3433/4885ALDH1A1 2922/4885 |
| US-20070111949-A1 | Modulating nitric oxide acitivity with glutathione-dependent formaldehyde dehydrogenase (GS-FDH); for treatment of asthma and impotency, angina, hypertension, and cancer; enzyme inhibitors | GGH, GSS, GSR | LMNA 4362/4885SMN1; SMN2 4483/4885ALDH1A1 129/4885 |
| US-20240238323-A1 | MODIFIED NUCLEOSIDES AND NUCLEOTIDES ANALOGS AS ANTIVIRAL AGENTS FOR CORONA AND OTHER VIRUSES | MTAP, PNP, SARS1 | LMNA 424/4885SMN1; SMN2 761/4885ALDH1A1 1929/4885 |
| US-20070037773-A1 | Methods and compositions for treating flaviviruses and pestiviruses | MTAP, PHOSPHO1, PNP | LMNA 1665/4885SMN1; SMN2 209/4885ALDH1A1 3300/4885 |
| US-20170166557-A1 | 6-SUBSTITUTED QUINAZOLINONE INHIBITORS | NDUFV3, NDUFV2, NDUFV1 | LMNA 1496/4885SMN1; SMN2 678/4885ALDH1A1 300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.